|
Latest Reports
|
| Date |
Description |
Country |
Analyst |
Download |
|
|
| 28-Jan-2024 |
Cipla Ltd - Drug launch delays & concentration risk are worrisome; Re-iterate SELL with TP Rs 1150 |
India |
Surya Patra |
 |
| 30-Oct-2023 |
Cipla - Strong Q2 but visible triggers priced-in; Maintain NEUTRAl with Pre-fixed TP of Rs 1070 |
India |
Surya Patra |
|
| 26-Jul-2023 |
Cipla (CIPLA IN): Visible triggers priced in; Downgrade to Neutral with pre-fixed TP Rs 1070 |
India |
Surya Patra |
|
| 14-May-2023 |
Cipla - gRevlimid covers more than the hit by delay in key launches: Maintain BUY with TP 1070 |
India |
Surya Patra |
|
| 26-Jan-2023 |
Cipla - Visible triggers priced-in; Maintain NEUTRAL with lowered TP Rs 1130 |
India |
Surya Patra |
|
| 06-Nov-2022 |
Cipla - gRevlimid is the Key near-term driver but priced-in; Downgrade to Neutral with lowered TP of Rs 1230: |
India |
Surya Patra |
|
| 01-Aug-2022 |
Cipla - Key new launches in H2 powers FY23 earnings; Maintain BUY with raised TP of Rs 1250 |
India |
Surya Patra |
|
| 11-May-2022 |
Cipla - Earnings momentum hinges on key drug launches; Maintain BUY with TP Rs1200 |
India |
Surya Patra |
|
| 26-Jan-2022 |
Cipla- Key drugs power earnings ahead; Buy with raised TP Rs 1250 |
India |
Surya Patra |
|
| 27-Oct-2021 |
Cipla - Key product opportunities to power earnings; Maintain BUY with TP Rs 1200 |
India |
Surya Patra |
|
| 06-Aug-2021 |
Cipla - Top 10 rank in US generics by Rx, complements ahead: BUY with raised TP Rs 1180 |
India |
Surya Patra |
|
| 15-May-2021 |
Cipla - Structural value growth on cards; BUY with TP of Rs 1100 |
India |
Surya Patra |
|
| 31-Jan-2021 |
Cipla (CIPLA IN) - Robust earnings visibility excites us; Maintain BUY with TP 1080 |
India |
Surya Patra |
|
| 14-Dec-2020 |
Cipla - Revlimid settlement boosts US outlook; Upgrade to BUY with raised TP of Rs 1040 |
India |
Surya Patra |
|
| 07-Nov-2020 |
Cipla - Covid portfolio surprised positively; Maintain Neutral with TP Rs 760 |
India |
Surya Patra |
|
| 10-Aug-2020 |
Cipla - All eyes on Albuterol execution in the US; Maintain Neutral with TP Rs 680 |
India |
Surya Patra |
|
| 17-May-2020 |
Cipla (CIPLA IN)- All hopes lies on Albuterol execution in US; Downgrade to Neutral with TP Rs 580 |
India |
Surya Patra |
|
| 06-Feb-2020 |
Cipla (CIPLA IN) - Business prioritisation augurs well |
India |
Surya Patra |
|
| 07-Nov-2019 |
Cipla (CIPLA IN) - No visible trigger in sight; Upgrade to NEU with TP Rs 460 |
India |
Surya Patra |
|
| 07-Aug-2019 |
Cipla (CIPLA IN) - Faces multiple growth challenges ahead; Downgrade to SELL with TP Rs 430 |
India |
Surya Patra |
|
| 22-May-2019 |
Cipla (CIPLA IN) - Strong Q4 but visible triggers priced-in; NEUTRAL TP Rs 510 |
India |
Jonas Bhutta |
|
| 07-Feb-2019 |
Cipla (CIPLA IN) - In line Q3; hopes for improved performance ahead; NEUTRAL with TP of Rs 510 |
India |
Surya Patra |
|
| 06-Nov-2018 |
Cipla (CIPLA IN) - Growth as well as profit outlook remains weak; Reiterate SELLwith TP of Rs 480 |
India |
Surya Patra |
|
| 08-Aug-2018 |
Cipla (CIPLA IN) - Profitability looks challenged; Downgrade to SELL with TP of Rs 510 |
India |
Surya Patra |
|
| 23-May-2018 |
Cipla - Weak quarter; hopes for improved performance ahead; NEUTRAL with TP of Rs 580 |
India |
Surya Patra |
|
|
|